Recruiting NA INTERVENTIONAL 1-arm NCT06101290

Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER) (LAYOVER)

Sponsor: National Cancer Institute (NCI)

Conditions Oligoprogressive Prostate Cancer Renal Cell Carcinoma Urothelial Carcinoma

Updated 5 times since 2023 Last updated: Dec 13, 2024 Started: Oct 5, 2023 Primary completion: Dec 5, 2025 Completion: Jan 5, 2031

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Oligoprogressive and Prostate Cancer, this trial is actively recruiting participants. The trial is conducted by National Cancer Institute (NCI) and has accumulated 5 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Jan 2025 — Present [monthly]

Recruiting NA
Sep 2024 — Jan 2025 [monthly]

Recruiting NA
Jul 2024 — Sep 2024 [monthly]

Recruiting NA
Jan 2024 — Jul 2024 [monthly]

Recruiting NA
Nov 2023 — Jan 2024 [monthly]

Recruiting NA

First recorded

Oct 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
University of California, Davis

Data source: University of California, Davis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sacramento, United States